Gap in secondary fracture prevention (but not in primary prevention of infection and thrombosis) following a hip fracture: the spare-hip prospective cohort
Prieto-Alhambra D., Vaquero-Cervino E., Torregrosa Suau OT., Teixidor Serra JT., Sierra Serrano JJS., Sanz-Amaro ., Sanz Sainz MS., Salomó Doménech MS., Sáez López PS., Rodríguez Martínez DR., Rodríguez Mañas LR., Olmos JM., Mora Fernández JM., Mills Gañan SM., Martínez Ros MM., Gutierrez Ganzarain AIG., Gonzalez García PG., Fernandez-Lombardia J., Ezquerra Herrando LE., Etxebarria-Foronda I., Díez Rodríguez AD., Díaz Miñarro JCD., Caeiro Rey C., Bañuelos Diaz AB., Balfagon Ferrer AB.
We assessed the proportion of patients on anti-osteoporosis treatment/s during a hospital admission for a hip fracture, and at 1- and 4-month follow-up. For comparison, we also report on anti-thrombotic and antibiotic therapies at these same times.